| P/E (FY) | 22.2 | Sales (TTM) | €763.7M |
| Earnings (TTM) | €136.9M | ROE | 24.63% |
| Net Margin | 17.92% | ROIC | 22.09% |
| Debt / Equity | 0.20 | TD / EBITDA | 0.55 |
| EPS Growth 3Y | −1.10% | Sales Growth 3Y | 5.59% |
Laboratorios Farmaceuticos Rovi, S.A. manufactures, markets and sells pharmaceutical products in Spain, the European Union, OECD countries and internationally. Its portfolio includes prescription medicines such as Enoxaparin Rovi, Hibor and Hirobriz Breezhaler, hospital products including imaging contrast agents and catheter care, and low-molecular-weight heparin and Okedi. The company also offers contract manufacturing for injectable forms such as prefilled syringes and vials. Incorporated in 1946, it is headquartered in Pozuelo de Alarcón and is a subsidiary of Norbel Inversiones, S.L.
| Market Cap | $3.45B | Trading Days | 4187 |
| 52W High | 86.70 |
| 52W Low | 51.65 |
| % Off High | −31.66% |
| YTD | −5.07% | 1Y | 5.95% |
| 3Y | 36.69% | 5Y | 7.96% |
| 10Y | 418.66% | Since incept. (ann.) | 15.00% |
| Ann. Volatility (1Y) | 29.27% | Ann. Volatility (3Y) | 30.04% |
| Sharpe (1Y) | 0.35 | Sharpe (3Y) | 0.49 |
| Max Drawdown (1Y) | −36.20% | Max Drawdown (3Y) | −48.98% |
| Beta (3Y, vs SPY) | 0.01 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ITGR | Integer Holdings Corp | $3.41B | 34.7 |
| RCUS | Arcus Biosciences, Inc. | $3.40B | — |
| RLAY | Relay Therapeutics, Inc. | $3.50B | — |
| OPCH | Option Care Health, Inc. | $3.53B | 17.7 |
| OGN | Organon & Co. | $3.55B | 18.8 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.55B | — |
| TLRY | Tilray Brands, Inc. | $3.59B | — |
| ADPT | Adaptive Biotechnologies Corp | $3.60B | — |
| NHC | NATIONAL HEALTHCARE CORP | $3.61B | 30.1 |
| 000100.KS | Yuhan Corp | $3.63B | 27.7 |
| ELVN | Enliven Therapeutics, Inc. | $3.27B | — |
| Scinai Immunotherapeutics Ltd. |
| $3.66B |
| — |
